Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Oncology and Capecitabine, with related work in Breast cancer, Observational study, Pembrolizumab. Notable publications include 'Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China', 'Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study', and 'Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised,...'.
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy
Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.
Clinicopathological characteristics and prognosis of Epstein-Barr virus–associated gastric cancer
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
Epidemiology, Prevention, and Treatment of Chemotherapy-Induced Myelosuppression in China: A National Cross-Sectional Study
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with <scp>HER2</scp>‐positive advanced breast cancer (<scp>PRETTY</scp>): A nationwide, prospective, observational study
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study
Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
Incidence of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Compliance in Chinese Real Clinical Setting: A Cross-Sectional Multicenter Survey